Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 6Myeloid 6Tumor-Agnostic 3Other solid neoplasm 3Gastrointestinal 3Classical hematology 3Lymphoid 2Head & Neck 2Other neoplasm 1Gynecologic 1

Conditions

Neoplasms 3

Interventions

pembrolizumab 62Paclitaxel 51Gemcitabine 50Carboplatin 45Docetaxel 43Cisplatin 31Pemetrexed 30Nivolumab 28Bevacizumab 28atezolizumab 22Fluorouracil 22Cetuximab 21Capecitabine 21Irinotecan 20Leucovorin 19Afatinib 18Erlotinib Hydrochloride 15trametinib 14Trastuzumab 13Ipilimumab 13130-nm albumin-bound paclitaxel 13regorafenib 11olaparib 11Sorafenib 11Oxaliplatin 11Drug Therapy 11eribulin 10enzalutamide 10Midazolam 10Injections 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × ON 01910 × Tumor-Agnostic × Clear all
NCT01165905 2017-06-23

Safety of 24-hour Infusion of ON 01910.Na in Combination With Gemcitabine in Advanced Solid Tumors

Traws Pharma, Inc.

Phase 1 Completed
10 enrolled
Tumor-Agnostic

Neoplasms

NCT01538537 2017-06-23

Safety of ON 01910.Na as a 3-day Infusion in Patients With Advanced Cancer

Traws Pharma, Inc.

Phase 1 Completed
29 enrolled
Tumor-Agnostic

Neoplasms

NCT01538563 2017-06-23

Safety of 24-Hour Infusion of ON 01910.Na in Patients With Advanced Cancer

Traws Pharma, Inc.

Phase 1 Completed
42 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡